Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S. Khodadoust, MD PhD, Tatyana A. Feldman, MD, Dok Hyun Yoon, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Dejan Radeski, MBBS, FRACP, FRCPA, Youn H. Kim, MD, Neha Mehta-Shah, MD, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Ryan A. Wilcox, MD, Won Seog Kim, MD PhD, Steven M. Horwitz, MD, Joseph J. Buggy, PhD, Andrew Hotson, PhD, Craig M. Hill, PhD, Brian Munneke, PhD, Suresh Mahabhashyam, MD, Richard A. Miller, MD, James W. Janc, PhD, Mehrdad Mobasher, MDMPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137782

Published: 2020

Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137631

Published: 2020

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Savita Bhalla, PhD, Kevin David, MD, Lauren Mauro, MD, Sheila Prachand, MS, Mint Sirisawad, Sriram Balasubramanian, PhD, Richard A. Miller, MD, Joseph Buggy, PhD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 3589.

https://doi.org/10.1182/blood.V110.11.3589.3589

Published: 2007

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

Journal Articles

Growth Inhibition or Apoptosis after Treatment with Motexafin Gadolinium and Celecoxib Is Cell Line Dependent and Correlates with p27 Levels.

Jason Ramos, PhD, Mint Sirisawad, BS, Jun Chen, PhD, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2005) 106 (11): 4296.

https://doi.org/10.1182/blood.V106.11.4296.4296

Published: 2005

Journal Articles

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Darren Magda, PhD, Philip Lecane, PhD, Mazen W. Karaman, PhD, Mint Sirisawad, PhD, Louie Naumovski, MD, PhD, Richard A. Miller, MD, Joseph G. Hacia, PhD

Blood (2005) 106 (11): 4827.

https://doi.org/10.1182/blood.V106.11.4827.4827

Published: 2005

Journal Articles

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium.

Jun Chen, PhD, Jason Ramos, PhD, Mint Sirisawad, BS, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2005) 106 (11): 4829.

https://doi.org/10.1182/blood.V106.11.4829.4829

Published: 2005

Journal Articles

Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Brad S. Kahl, MD, Ranjana Advani, MD, Neil Kay, MD, Izidore S. Lossos, MD, Andrew Evens, DO, Leo Gordon, MD, Richard A. Miller, MD, See-Chun Phan, MD

Blood (2005) 106 (11): 4758.

https://doi.org/10.1182/blood.V106.11.4758.4758

Published: 2005

Journal Articles

Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

Louie Naumovski, MD-PhD, Mint Sirisawad, BA, Philip Lecane, PhD, Jason Ramos, PhD, Darren Magda, PhD, Zhong Wang, PhD, Patti Thiemann, BS, Garry Boswell, PharmD, Dong-Gyu Cho, BS, Jonathan Sessler, PhD, Richard A. Miller, MD

Blood (2004) 104 (11): 2501.

https://doi.org/10.1182/blood.V104.11.2501.2501

Published: 2004

Journal Articles

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines.

Jun Chen, PhD, Jason Ramos, PhD, Mint Sirisawad, BA, Richard A. Miller, MD, Louie Naumovski, MD-PhD

Blood (2004) 104 (11): 2296.

https://doi.org/10.1182/blood.V104.11.2296.2296

Published: 2004

Journal Articles

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Thomas S. Lin, MD, PhD, Sabyasachi Biswas, PhD, Louie Naumovski, MD, PhD, Phillip Lecane, PhD, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Andrew P. Mone, MD, PhD, David M. Lucas, PhD, See-Chun Phan, MD, Richard A. Miller, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3486.

https://doi.org/10.1182/blood.V104.11.3486.3486

Published: 2004

Journal Articles

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Louie Naumovski, MD-PhD, Jason Ramos, PhD, Jun Chen, PhD, Mint Sirisawad, BA, David Lucas, PhD, John C. Byrd, MD, Richard A. Miller, MD

Blood (2004) 104 (11): 3406.

https://doi.org/10.1182/blood.V104.11.3406.3406

Published: 2004

NARROW

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Growth Inhibition or Apoptosis after Treatment with Motexafin Gadolinium and Celecoxib Is Cell Line Dependent and Correlates with p27 Levels.

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium.

Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines.

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only